MedPath

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Completed
Conditions
Myocardial Infarction, Acute
Interventions
Other: No intervention
Registration Number
NCT05692752
Lead Sponsor
Islamia University of Bahawalpur
Brief Summary

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Detailed Description

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, \> 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated.

Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  1. Patients diagnosed with ST-Elevated Myocardial Infarction will be identified at the Coronary Care Unit at Ain-shams University hospital
  2. Acute episode of Myocardial Infarction
  3. With No history of previous Myocardial Infarction Treatment
Exclusion Criteria
  1. Patients not diagnosed with ST-Elevated Myocardial Infarction and healthy at the Coronary Care Unit at Ain-shams 2. University hospital
  2. Previously Known patients of Myocardial infacrtion
  3. Previous medication

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Test GroupNo interventionThe study group included 10 patients, 1. men and women 2. between age of 35-60 year 3. chest pain lasting for at least 30 minutes, 4. electrocardiogram (ECG) finding that display ST-segment elevation (STEMI)
Control GroupNo interventionThe study group included 10 patients, 1. men and women 2. between age of 35-60 year 3. having no complaint of health issue,
Primary Outcome Measures
NameTimeMethod
Expression of miR-208b48 hours from the onset of the infarct

Expression during episodes of myocardial infarction

Expression of miR-133a48 hours from the onset of the infarct

Expression during episodes of myocardial infarction

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance Al Tagamoa Al Khames

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath